# US 2008/0075688 A1 · Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0075688 A1
- Document ID: US20080075688A1
- Status: Published application
- Kind: A1
- Application number: 11/977,098
- Filed: 2007-10-23
- Published: 2008-03-27
- Earliest claimed: 2003-10-31
- Assignees: The Procter & Gamble Company
- Inventors: Bryn Hird; Ronald Jandacek
- Web page: https://patentgrep.com/patent/US20080075688A1

## CPC

- A61K 31/74: Synthetic polymeric materials
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This disclosure relates to compositions comprising an open-celled polymeric foam wherein the compositions are useful for sequestering lipophilic materials present in the gastrointestinal tract, thereby inhibiting the absorption of such lipophilic materials by the body. The disclosure further relates to compositions comprising the open-celled polymeric foam wherein the compositions are useful for ameliorating side effects associated with the use of lipase inhibitors. In a preferred embodiment, this disclosure relates to compositions comprising polymeric foam materials made from high internal phase emulsions, where such foams are useful for sequestering lipophilic materials. Further disclosed are compositions comprising open-celled polymeric foams wherein the compositions are useful for the purpose of sequestering aqueous and/or hydrophilic materials present in the gastrointestinal tract, thereby ameliorating diarrhea. Kits comprising the compositions and methods of using the compositions and kits are also described.

## Claims

### Claim at position 1

-9. (canceled)

### Claim 10

A method of sequestering lipophilic materials present in the gastrointestinal tract of an animal comprising administration of a composition comprising a non-digestible, non-absorbable, open-celled polymeric foam to the animal.

### Claim 11 (depends on 10)

The method according to claim 10 wherein the foam has a density of less than about 0.1 g/cc.

### Claim 12 (depends on 11)

The method according to claim 11 wherein the foam is a HIPE foam.

### Claim 13 (depends on 12)

The method according to claim 12 wherein the composition is administered in an amount which is from about 0.02% to about 2% of the diet of the animal, by weight of the diet on a dry basis.

### Claim 14 (depends on 12)

The method according to claim 12 further comprising administration of a lipase inhibitor to the animal.

### Claim 15 (depends on 14)

The method according to claim 14 wherein the composition comprises the lipase inhibitor and wherein the lipase inhibitor is selected from the group consisting of 2-amino-4H-3,1-benzoxazin-4-ones; 2-oxy-4H-3,1-benzoxazin-4-ones; 2-thio-4H-3,1-benzoxazin-4-ones; tetrahydrolipstatin and its derivatives; chiral alkylphosphonates; chiral isomers of beta-lactone; and mixtures thereof.

### Claim 16 (depends on 15)

The method according to claim 15 wherein the lipase inhibitor is a compound having the structure:
wherein A is the group

### Claim 17

A method selected from the group consisting of treating gastrointestinal distress, treating fecal urgency, treating obesity, treating hyperlipidemia, treating diarrhea, inhibiting anal leakage, reducing levels of toxic substances, reducing blood cholesterol levels, inducing satiety, effecting weight loss, effecting weight control, treating Type II Diabetes, delaying onset of Type II Diabetes, preventing Type II Diabetes, and combinations thereof in an animal, the method comprising administration of a composition comprising a non-digestible, non-absorbable, open-celled polymeric foam to the animal.

### Claim 18 (depends on 17)

The method according to claim 17 wherein the foam is a HIPE foam.

### Claim 19 (depends on 18)

The method according to claim 18 wherein the composition is administered in an amount which is from about 0.02% to about 2% of the diet of the animal, by weight of the diet on a dry basis.

### Claim 20 (depends on 18)

The method according to claim 18 further comprising administration of a lipase inhibitor to the animal.

### Claim 21 (depends on 20)

The method according to claim 20 wherein the composition comprises the lipase inhibitor and wherein the lipase inhibitor is selected from the group consisting of 2-amino-4H-3,1-benzoxazin-4-ones; 2-oxy-4H-3,1-benzoxazin-4-ones; 2-thio-4H-3,1-benzoxazin-4-ones; tetrahydrolipstatin and its derivatives; chiral alkylphosphonates; chiral isomers of beta-lactone; and mixtures thereof.

### Claim 22 (depends on 21)

The method according to claim 21 wherein the lipase inhibitor is a compound having the structure:
wherein A is the group,

### Claim at position 15

-28. (canceled)
